Significant political momentum toward rescheduling psychedelics like Ibogaine for PTSD treatment could lower federal barriers.

Highlighted for having the broadest pipeline in the psychedelics space amid potential fast-track research for veterans.

Experiencing a bullish momentum shift due to high-profile political endorsements and potential executive actions in the US.

Benefiting from positive political tailwinds and a potential executive order on psychedelics.

Beneficiary of a U.S. executive order providing a catalyst for the sector and bypassing legislative hurdles.

Positioned as a leader in the psychedelic medicine space with a strong IP portfolio and positive clinical data for its 5-MeO-DMT treatment. The speaker believes the market is underestimating its potential to become a first-line treatment for various mental health issues.